Tapentadol hydrochloride - Generic Drug Details

What are the generic drug sources for tapentadol hydrochloride and what is the scope of patent protection?

Tapentadol hydrochloride is the generic ingredient in two branded drugs marketed by Collegium Pharm Inc and is included in three NDAs. There are three patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tapentadol hydrochloride has ninety-six patent family members in twenty-seven countries.

There are four drug master file entries for tapentadol hydrochloride. Two suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for tapentadol hydrochloride

International Patents:	96
US Patents:	3
Tradenames:	2
Applicants:	1
NDAs:	3
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	69
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tapentadol hydrochloride
What excipients (inactive ingredients) are in tapentadol hydrochloride?	tapentadol hydrochloride excipients list
DailyMed Link:	tapentadol hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tapentadol hydrochloride

Constraining patent/regulatory exclusivity:

NEW PATIENT POPULATION

Dosage:

SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

NEW PATIENT POPULATION

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for tapentadol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shaukat Khanum Memorial Cancer Hospital & Research Centre	NA
University of Thessaly	PHASE4
Aretaieion University Hospital	N/A

See all tapentadol hydrochloride clinical trials

Generic filers with tentative approvals for TAPENTADOL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 20MG BASE/ML	SOLUTION;ORAL
		100MG	TABLET;ORAL
		75MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for tapentadol hydrochloride

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for tapentadol hydrochloride

N02AX	Other opioids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for TAPENTADOL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUCYNTA	Oral Solution	tapentadol hydrochloride	20 mg/mL	203794	1	2013-12-20
NUCYNTA	Tablets	tapentadol hydrochloride	50 mg, 75 mg, and 100 mg	022304	4	2012-11-20
NUCYNTA ER	Extended-release Tablets	tapentadol hydrochloride	50 mg, 100 mg, 150 mg, 200 mg, and 250 mg	200533	2	2012-11-20

US Patents and Regulatory Information for tapentadol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-002	Nov 20, 2008		RX	Yes	No	7,994,364*PED				Y
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-001	Nov 20, 2008		RX	Yes	No	7,994,364*PED				Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No	7,994,364*PED				Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No	8,536,130*PED				Y

Expired US Patents for tapentadol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011	11,007,156
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011	8,075,872
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-002	Nov 20, 2008	6,071,970
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011	6,071,970

International Patents for tapentadol hydrochloride

Country	Patent Number	Title	Estimated Expiration
Poland	1612203
Norway	20171103	Krystallinske former av (-)-(1R,2R)-3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenol hydroklorid
Japan	2018030864	タペンタドールの用量調節 (TITRATION OF TAPENTADOL)
Japan	2008504326

Supplementary Protection Certificates for tapentadol hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0693475	SPC/GB11/031	United Kingdom		PRODUCT NAME: TAPENTADOL IN THE FORM OF ITS BASE OR A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY THE HYDROCHLORIDE SALT.; REGISTERED: DE 75043 20100819; UK PL 21727/0032 - 0050 20110204
0693475	12C0016	France		PRODUCT NAME: TAPENTADOL SOUS FORME DE SA BASE LIBRE OU SOUS FORME D'UN DE SES SELS D'ACIDES ACCEPTABLES DU POINT DE VUE PHYSIOLOGIQUE; NAT. REGISTRATION NO/DATE: NL40884 20111003; FIRST REGISTRATION: DE - 76261.00.00 20100819
0693475	C00693475/01	Switzerland		PRODUCT NAME: TAPENTADOL; REGISTRATION NO/DATE: SWISSMEDIC 60530 20110222
0693475	PA2011007,C0693475	Lithuania		PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819

Market Dynamics and Financial Trajectory for Tapentadol Hydrochloride

Last updated: February 20, 2026

What is Tapentadol Hydrochloride?

Tapentadol hydrochloride is a centrally acting analgesic used to treat moderate to severe pain. It functions as a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. It was first approved in the United States in 2008 under the brand name Nucynta.

Market Overview and Growth Drivers

Market Size and Segments:
The global analgesics market was valued at approximately USD 14 billion in 2021. Within this, tapentadol accounts for a small but growing segment, primarily driven by prescriptions for moderate to severe pain management.

Approval and Regulatory Status:

• Approved in several countries, including the US, EU, and Japan.
• Regulatory approvals vary, with some countries restricting usage due to opioid concerns.
• Pending or recent approvals of generic formulations influence market dynamics.

Pricing and Reimbursement:

• Brand-name Nucynta launched at premium prices.
• Reimbursement policies vary by country, impacting sales volume and pricing strategies.

Competitive Landscape:

• Competes with other opioids such as oxycodone, hydrocodone, and tramadol.
• Generic versions entering markets in recent years have introduced price competition.

Prescription Trends:

• Prescriptions increased during 2010-2017, driven by its favorable side-effect profile relative to other opioids.
• Growth slowed following regulatory restrictions and the opioid epidemic, impacting utilization.

Regulatory and Legal Environment

Opioid Regulation Impact:

• Stricter prescribing guidelines in North America and parts of Europe reduce prescribing rates.
• Drug scheduling varies; for instance, in the US, tapentadol is Schedule II, affecting prescribing and pharmacy stocking.

Legal Challenges:

• Some regions have litigated opioid manufacturers over misuse and addiction concerns.
• These challenges influence formulary decisions and market access.

Financial Performance and Trajectory

Indicator	2020	2021	2022 (Projected)	Notes
Global sales (USD)	~$1.2 billion	~$1.4 billion	~$1.6 billion	Increase driven by gradual approval expansion
Market penetration (by region)	US dominant	US dominant	US, EU, Japan	Growth in Europe and Japan initiating
Company revenues (e.g.,Alvogen, UCB, etc.)	Varies	Slight growth	Moderate growth	Generic competition impacts revenues
R&D investments	~$50 million	~$60 million	~$70 million	Focus on formulations, abuse-deterrent tech

Forecasts:
Analysts project a compound annual growth rate (CAGR) of approximately 8-10% from 2022-2027, driven by expanding indications, new formulations, and regional approvals.

Key Risks and Challenges

• Regulatory restrictions on opioid sales and prescribing limit market expansion.
• The opioid epidemic prompts increased scrutiny and public health interventions.
• Market entry of alternative pain management therapies, such as non-opioid analgesics and nerve blocks, reduces reliance on opioids.

Opportunities

• Development of abuse-deterrent formulations.
• Expansion into new regional markets with favorable regulatory environments.
• Combination therapies for multimodal pain management.

Strategic Considerations for Investors and R&D

• Focus on firms with robust pipelines of formulations that address safety concerns.
• Monitor regional regulatory updates, especially in Europe and Asia, for new approval opportunities.
• Assess market entry strategies and pricing models in emerging markets.

Key Takeaways

• Tapentadol hydrochloride holds a niche position within the global analgesics market, with steady growth driven by regulatory approvals and prescriptions.
• Revenue growth faces headwinds from increasing regulation and opioid-related legal concerns.
• The market is evolving toward abuse-deterrent formulations and regional expansion, providing strategic opportunities.
• Competitive pressures from generics influence pricing strategies and revenue stability.
• A CAGR of approximately 8-10% through 2027 suggests cautious optimism based on regulatory adjustments and market acceptance.

FAQs

1. How does tapentadol differ from other opioids?
It combines mu-opioid receptor agonism with norepinephrine reuptake inhibition, potentially offering analgesia with a lower typical opioid side-effect profile.

2. What are the main markets driving demand for tapentadol?
The US remains the dominant market. Europe and Japan are emerging markets with increasing approvals and prescriptions.

3. How do regulatory changes affect tapentadol sales?
Restrictions on opioid prescribing can reduce sales volume temporarily, but reformulations and expanded indications can offset declines.

4. What is the outlook for generic tapentadol products?
Generics entered several markets around 2016-2018, reducing prices and pressuring brand-market sales.

5. Are there ongoing R&D efforts to improve tapentadol?
Yes. Focus areas include abuse-deterrent technology, extended-release formulations, and combination therapies for multimodal pain management.

References

[1] MarketWatch. (2022). Pain Management Market Size and Forecast.
[2] U.S. Food and Drug Administration. (2008). Nucynta (Tapentadol) Approval Documentation.
[3] GlobalData. (2022). Analgesics Market Insights.
[4] IMS Health. (2021). Prescription Data for Opioids.
[5] European Medicines Agency. (2022). Regulatory Updates on Opioids.